Abstract
Peripheral administration of the unsulphated cholecystokinin octapeptide (CCK-8us) led to an anxiogenic-like action in the elevated plus-maze model of anxiety in rats. Devazepide and L-365, 260 showed potent anxiolytic-like effects at similar doses. The fact that devazepide is 1000 times more potent as a CCK-A receptor antagonist than L-365, 260, whereas the two compounds are nearly equipotent at the CCK-B receptor subtype, suggests that CCK-B rather than CCK-A receptors are involved in these effects. Similar results were obtained in mice using the two-compartment test. In the elevated plus-maze, the benzodiazepine antagonist, flumazenil, which was inactive when given alone, significantly antagonized the anxiogenic-like activity of CCK-8us and the anxiolytic-like effects of devazepide and L-365, 260. These results suggest a complex interaction between benzodiazepine and CCK receptor mechanisms in the regulation of anxiety states.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Assié MB, Chopin P, Stenger A, Palmier C, Briley M (1992) Neuropharmacology of a new potential anxiolytic compound, F 2692, 1-(3′-trifluoromethyl phenyl) 1, 4-dihydro 3-amino 4-oxo 6-methyl pyridazine: 1. Acute and in vivo effects. Psychopharmacology (in press)
Baldwin HA, File SE (1988) Reversal of increased anxiety during benzodiazepine withdrawal: evidence for an anxiogenic endo genous ligand for the benzodiazepine receptor. Brain Res Bull 20:603–606
Bouthillier A, De Montigny C (1988) Long-term benzodiazepine treatment reduces neuronal responsiveness to cholecystokinin: an electrophysiological study in the rat. Eur J Pharmacol 151:135–138
Bradwejn J, De Montigny C (1984) Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurons. Nature 312:363–364
Bradwejn J, De Montigny C (1985) Effects of PK 8165, a partial benzodiazepine receptor agonist, on cholecystokinin-induced activation of hippocampal pyramidal neurons: a microiontophoretic study in the rat. Eur J Pharmacol 112:415–418
Bradwejn J, Koszycki D, Meterissian G (1990) Cholecystokinin tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 35:83–85
Bradwejn J, Koszycki D, Shriqui C (1991) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch Gen Psychiatry 48:603–610
Chopin P, Briley M (1987) Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission. TIPS 8:383–388
Chopin P, Pellow S, File SE (1986) The effects of yohimbine on exploratory and locomotor behaviour are attributable to its effects at noradrenaline and not at benzodiazepine receptors. Neuropharmacology 25:53–57
Chopin P, Assié MB, Briley M (1992) Neuropharmacology of a new potential anxiolytic compound, F 2692, 1-(3′-trifluoromethyl phenyl) 1,4-dihydro 3-amino 4-oxo 6-methyl pyridazine: 2. Evaluation of its tolerance and dependence producing potential and of its effects on benzodiazepine withdrawal in the elevated plus-maze test in rats. Psychopharmacology (in press)
Costall B, Domeney AM, Hughes J, Kelly ME, Naylor RJ, Woodruff GN (1991) Anxiolytic effects of CCK-B antagonists. Neuropeptides 19:65–73
Crawley JN (1988) Neuronal cholecystokinin. ISI Atlas Pharmacol 2:84–90
Crawley JN, Goodwin FK (1980) Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 13:167–170
De Montigny C (1989) Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch Gen Psychiatry 46:511–517
File SE, Pellow S (1985) Does the benzodiazepine receptor antagonist Ro 15-1788 antagonize the reductions in social and exploratory behaviour produced by picrotoxin and pentylenetetrazole? Arch Int Pharmacodyn Ther 277:272–279
Harro J, Vasar E (1991) Evidence that CCCB receptors mediate the regulation of exploratory behaviour in the rat. Eur J Pharmacol 193:379–381
Harro J, Lang A, Vasar E (1990a) Long-term diazepam treatment produces changes in cholecystokinin receptor binding in rat brain. Eur J Pharmacol 180:77–83
Harro J, Kiivet RA, Lang A, Vasar E (1990b) Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics. Behav Brain Res 39:63–71
Hendrie CA, Dourish CT (1990) Anxiolytic profile of the cholecystokinin antagonist devazepide in mice. Br J Pharmacol 99:138P
Hill DR, Campdell NJ, Shaw TM, Woodruff GN (1987) Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective non-peptide CCK antagonists. J Neurosci 7:2967–2976
Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 17:6728–6732
Itonaga M, Uruno T, Kubota K (1988) Cholecystokinin antagonism byβ-carboline esters in the central nervous system in mice. Jpn J Pharmacol 46:319–324
Kilfoil T, Michel A, Montgomery D, Whiting RL (1989) Effects of anxiolytic and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice. Neuropharmacology 28:901–905
Kosaka T, Kosaka K, Tateishi K, Hamaoka Y, Yanaihara N, Wu JY, Hama K (1985) GABAergic neurons containing CCK-8-like and or VIP-like immunoreactivities in the rat hippocampus and dentate gyrus. J Comp Neurol 239:420–430
Kubota K, Itonaga M (1986)β-carbolines selectively antagonize the cholecystokinin action in isolated guinea-pig gallblader muscle. Jpn J Pharmacol 42:501–506
Kubota K, Sunagane N, Sugaya K, Uruno T, Matsuoka Y (1983) Competitive antagonism of cholecystokinin and some benzodiazepines at cholecystokinin receptors of smooth muscle. Jpn J Pharmacol 33:87P
Kubota K, Sugaya K, Matsuda I, Matsuoka Y, Terawaki Y (1985) Reversal of antinociceptive effect of cholecystokinin by benzodiazepines and a benzodiazepine antagonist, Ro 15-1788. Jpn J Pharmacol 37:101–105
Kubota K, Matsuda I, Sugaya K, Uruno T (1986) Cholecystokinin antagonism by benzodiazepines in the food intake in mice. Physiol Behav 36:175–178
Moran TH, Robinson PH, Goldrich MS, McHugh PR (1986) Two brain cholecystokinin receptors: implications for behavioural actions. Brain Res 362:175–179
Pellow S, Chopin P, File SE, Briley M (1985) Validation of open: closed arms entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149–167
Ravard S, Dourish CT (1990) Cholecystokinin and anxiety. TIPS 11:271–273
Ravard S, Dourish CT, Iversen SD (1990) Evidence that the anxiolytic-like effects of CCK antagonists devazepide and L-365, 260 in the elevated plus-maze paradigm in rats are mediated by CCK receptors. Br J Pharmacol 101:576P
Singh L, Field MJ, Hughes J, Vass CA, Woodruff GN (1991a) Central administration of a CCK-B receptor agonist induces anxiety. Br J Pharmacol 102:45P
Singh L, Lewis AS, Field MJ, Hughes J, Woodruff GN (1991b) Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc Natl Acad Sci USA 8:1130–1133
Singh L, Field MJ, Hughes J, Menzies R, Oles RJ, Vass CA, Woodruff GN (1991c) The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist. Br J Pharmacol 104:239–245
Singh L, Field MJ, Vass CA, Hughes J, Woodruff GN (1992) The antagonism of benzodiazepine withdrawal effects by the selective cholecystokininB receptor antagonist CI-988. Br J Pharmacol 105:8–10
Sugaya K, Matsuda I, Kubota K (1985) Inhibition of hypothermic effect of cholecystokinin by benzodiazepines and a benzodiazepine antagonist, Ro 15-1788, in mice. Jpn J Pharmacol 39:277–280
Sugaya K, Matsuda I, Kubota K (1987) Possible involvement of the CCK receptor in the benzodiazepine antagonism to CCK in the mouse brain. Jpn J Pharmacol 43:67–71
Yaksh TL, Furui T, Kanawati IS, Go VLW (1987) Release of cholecystokinin from rat cerebral cortex in vivo: role of GABA and glutamate receptor systems. Brain Res 406:207–214
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chopin, P., Briley, M. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology 110, 409–414 (1993). https://doi.org/10.1007/BF02244646
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244646